<p>Capital &amp; Planning LLC 在最近向美國證券交易委員會提交的 13F 文件中表示，在第二季度將其在艾伯維公司（NYSE:ABBV - 免費報告）的持股減少了 81.2%。該公司在季度內出售了 5,000 股後，持有 1,155 股艾伯維的股票。根據其最近的 SEC 文件，Capital &amp; Planning LLC 在艾伯維的持股價值為 214,000 美元。</p>
<ul>
<li>隨着市場輪動，這隻醫療保健 ETF 引領潮流</li>
</ul>
<p>其他機構投資者和對沖基金最近也調整了對該公司的持股。先鋒集團（Vanguard Group Inc.）在第一季度將其在艾伯維的持股增加了 0.5%。先鋒集團目前持有 173,917,865 股艾伯維的股票，價值 36,439,271,000 美元，此前在該期間又購買了 845,787 股。北方信託公司（Northern Trust Corp）在第一季度將其在艾伯維的持股增加了 0.9%。北方信託公司目前持有 22,013,920 股艾伯維的股票，價值 4,612,357,000 美元，此前在該期間又購買了 189,294 股。高盛集團（Goldman Sachs Group Inc.）在第一季度將其在艾伯維的持股增加了 31.6%。高盛集團目前持有 14,646,908 股艾伯維的股票，價值 3,068,820,000 美元，此前在該期間又購買了 3,519,187 股。瑞銀資產管理（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度將其在艾伯維的持股增加了 5.9%。瑞銀資產管理目前持有 12,771,854 股艾伯維的股票，價值 2,675,959,000 美元，此前在該期間又收購了 713,148 股。最後，Dimensional Fund Advisors LP 在第一季度將其在艾伯維的持股增加了 0.5%。Dimensional Fund Advisors LP 目前持有 9,413,033 股艾伯維的股票，價值 1,972,050,000 美元，此前在該期間又收購了 45,871 股。70.23% 的股票由機構投資者持有。</p>
<h2>分析師評級上調與下調</h2>
<p>多家研究公司最近對 ABBV 進行了評估。富國銀行（Wells Fargo &amp; Company）在 9 月 12 日的研究報告中將艾伯維的目標股價從 240.00 美元上調至 260.00 美元，並給予該公司 “增持” 評級。貝倫貝格銀行（Berenberg Bank）在 9 月 17 日的研究報告中將艾伯維的評級從 “持有” 上調至 “買入”，並將其目標股價從 170.00 美元上調至 270.00 美元。Cantor Fitzgerald 在 9 月 15 日的研究報告中將艾伯維的目標股價從 215.00 美元上調至 245.00 美元，並給予該公司 “增持” 評級。Evercore ISI 在 9 月 22 日的報告中將艾伯維的目標股價從 207.00 美元上調至 222.00 美元，並給予該公司 “跑贏大盤” 評級。最後，派珀·桑德勒（Piper Sandler）在 8 月 12 日的報告中開始覆蓋艾伯維的股票。他們給予 “增持” 評級，並設定 231.00 美元的目標股價。四位股票研究分析師對該股票給予強烈買入評級，十七位給予買入評級，八位給予持有評級。根據 MarketBeat 的數據，艾伯維的共識評級為 “適度買入”，共識目標價為 223.52 美元。</p>
<ul>
<li>艾伯維股票關注突破，管道與利潤增長</li>
</ul>
<p><strong>獲取我們對 ABBV 的最新股票分析</strong></p>
<h2>艾伯維股票下跌 3.0%</h2>
<p>艾伯維（ABBV）股票在週五開盤價為 236.98 美元。艾伯維公司 12 個月低點為 163.81 美元，12 個月高點為 244.81 美元。該公司的 50 日移動平均線為 209.90 美元，200 日移動平均線為 195.87 美元。該股票的市值為 4186.3 億美元，市盈率為 112.85，市盈增長比率為 1.43，貝塔值為 0.51。該公司的流動比率為 0.74，速動比率為 0.61，債務與股本比率為 44.14。</p>
<ul>
<li>3 家生物科技巨頭受益於美國銷售和政策變化</li>
</ul>
<p>艾伯維（NYSE:ABBV - 獲取免費報告）最近在 7 月 31 日宣佈了其財報。該公司報告本季度每股收益為 2.97 美元，低於共識預期的 3.24 美元，差額為 0.27 美元。艾伯維的股本回報率為 699.66%，淨利潤率為 6.45%。該公司本季度的收入為 154.2 億美元，而共識預期為 149.3 億美元。去年同期，該公司的每股收益為 2.65 美元。與去年同期相比，該公司的季度收入增長了 6.6%。股票研究分析師預測，艾伯維公司今年將發佈 12.31 美元的每股收益。</p>
<h2>艾伯維宣佈分紅</h2>
<p>該公司最近還宣佈了季度分紅，將於 11 月 14 日（星期五）支付。10 月 15 日（星期三）的登記投資者將獲得 1.64 美元的分紅。除息日為 10 月 15 日（星期三）。這代表着年化分紅為 6.56 美元，分紅收益率為 2.8%。艾伯維的分紅支付比率（DPR）目前為 312.38%。</p>
<h2>內部人士下注</h2>
<p>在其他艾伯維新聞中，執行副總裁 Azita Saleki-Gerhardt 於 8 月 12 日出售了 42,370 股該公司的股票。該股票以平均價格 198.42 美元出售，總價值為 8,407,055.40 美元。交易完成後，該執行副總裁直接持有 177,292 股該公司的股票，價值 35,178,278.64 美元。此交易代表其持股減少了 19.29%。該交易已在向證券交易委員會的備案中披露，相關信息可通過 SEC 網站訪問。此外，執行副總裁 Nicholas Donoghoe 於 8 月 5 日出售了 13,295 股該公司的股票。該股票以平均價格 198.51 美元出售，總交易額為 2,639,190.45 美元。交易完成後，該執行副總裁直接持有 58,247 股該公司的股票，價值約 11,562,611.97 美元。這代表其持股減少了 18.58%。該銷售的披露信息可在此處找到。公司內部人士目前持有 0.25% 的股票。</p>
<h2>艾伯維公司簡介</h2>
<p>（免費報告）</p>
<p>艾伯維公司在全球範圍內發現、開發、生產和銷售藥品。該公司提供的藥物包括：Humira，一種用於自身免疫性疾病和腸道貝赫切特病及膿皰性壞死性皮膚病的注射劑；Skyrizi，用於治療中度至重度斑塊型銀屑病、銀屑病性疾病和克羅恩病；Rinvoq，用於治療類風濕性關節炎、銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸性脊柱關節炎、潰瘍性結腸炎和克羅恩病；Imbruvica，用於治療成人血癌患者；Epkinly，用於治療淋巴瘤；Elahere，用於治療癌症；以及 Venclexta/Venclyxto，用於治療血癌。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們認為比艾伯維更好的股票</li>
<li>投資者如何識別併成功交易下跌缺口股票</li>
<li>通用動力創下新高：為什麼它可能會繼續上漲</li>
<li>如何計算股票利潤</li>
<li>耐克的逆轉：如果鞋子合適，就買下它！</li>
<li>如何有效使用 MarketBeat 評級篩選器</li>
<li>英偉達突破新高：接下來會發生什麼？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在艾伯維嗎？</h2>
<p>在考慮艾伯維之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而艾伯維並不在名單上。</p>
<p>雖然艾伯維目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

艾伯維

高盛

<p>Capital & Planning LLC 已將其在艾伯維（AbbVie Inc.，NYSE:ABBV）的持股比例減少了 81.2%，出售了 5,000 股，保留了 1,155 股，價值 214,000 美元。其他機構投資者，包括先鋒集團（Vanguard）和高盛（Goldman Sachs），則增加了在艾伯維的持股。分析師們提高了對艾伯維的目標價，普遍評級為 “適度買入”，目標價為 223.52 美元。艾伯維的股票開盤價為 236.98 美元，12 個月的價格區間為 163.81 美元至 244.81 美元。該公司報告上個季度每股收益為 2.97 美元，未達到預期，但收入同比增長了 6.6%</p>

<p>Capital &amp; Planning LLC trimmed its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 81.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,155 shares of the company's stock after selling 5,000 shares during the quarter. Capital &amp; Planning LLC's holdings in AbbVie were worth $214,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Capital &amp; Planning LLC 在最近向美國證券交易委員會提交的 13F 文件中表示，在第二季度將其在艾伯維公司（NYSE:ABBV - 免費報告）的持股減少了 81.2%。該公司在季度內出售了 5,000 股後，持有 1,155 股艾伯維的股票。根據其最近的 SEC 文件，Capital &amp; Planning LLC 在艾伯維的持股價值為 214,000 美元。</p>
</div><ul>
<li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li>
</ul>
<div class="lb-trans"><ul>
<li>隨着市場輪動，這隻醫療保健 ETF 引領潮流</li>
</ul>
</div><p>Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in AbbVie by 0.5% in the first quarter. Vanguard Group Inc. now owns 173,917,865 shares of the company's stock valued at $36,439,271,000 after buying an additional 845,787 shares during the period. Northern Trust Corp raised its stake in AbbVie by 0.9% in the first quarter. Northern Trust Corp now owns 22,013,920 shares of the company's stock valued at $4,612,357,000 after buying an additional 189,294 shares during the period. Goldman Sachs Group Inc. raised its stake in AbbVie by 31.6% in the first quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company's stock valued at $3,068,820,000 after buying an additional 3,519,187 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in AbbVie by 5.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 12,771,854 shares of the company's stock valued at $2,675,959,000 after acquiring an additional 713,148 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in AbbVie by 0.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 9,413,033 shares of the company's stock valued at $1,972,050,000 after acquiring an additional 45,871 shares during the period. 70.23% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金最近也調整了對該公司的持股。先鋒集團（Vanguard Group Inc.）在第一季度將其在艾伯維的持股增加了 0.5%。先鋒集團目前持有 173,917,865 股艾伯維的股票，價值 36,439,271,000 美元，此前在該期間又購買了 845,787 股。北方信託公司（Northern Trust Corp）在第一季度將其在艾伯維的持股增加了 0.9%。北方信託公司目前持有 22,013,920 股艾伯維的股票，價值 4,612,357,000 美元，此前在該期間又購買了 189,294 股。高盛集團（Goldman Sachs Group Inc.）在第一季度將其在艾伯維的持股增加了 31.6%。高盛集團目前持有 14,646,908 股艾伯維的股票，價值 3,068,820,000 美元，此前在該期間又購買了 3,519,187 股。瑞銀資產管理（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度將其在艾伯維的持股增加了 5.9%。瑞銀資產管理目前持有 12,771,854 股艾伯維的股票，價值 2,675,959,000 美元，此前在該期間又收購了 713,148 股。最後，Dimensional Fund Advisors LP 在第一季度將其在艾伯維的持股增加了 0.5%。Dimensional Fund Advisors LP 目前持有 9,413,033 股艾伯維的股票，價值 1,972,050,000 美元，此前在該期間又收購了 45,871 股。70.23% 的股票由機構投資者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>A number of research firms recently weighed in on ABBV. Wells Fargo &amp; Company increased their price target on AbbVie from $240.00 to $260.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, September 12th. Berenberg Bank raised shares of AbbVie from a &#34;hold&#34; rating to a &#34;buy&#34; rating and increased their price objective for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. Cantor Fitzgerald increased their price objective on shares of AbbVie from $215.00 to $245.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, September 15th. Evercore ISI increased their price target on shares of AbbVie from $207.00 to $222.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, September 22nd. Finally, Piper Sandler started coverage on shares of AbbVie in a report on Tuesday, August 12th. They issued an &#34;overweight&#34; rating and a $231.00 price target on the stock. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, AbbVie has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $223.52.</p>
<div class="lb-trans"><p>多家研究公司最近對 ABBV 進行了評估。富國銀行（Wells Fargo &amp; Company）在 9 月 12 日的研究報告中將艾伯維的目標股價從 240.00 美元上調至 260.00 美元，並給予該公司 “增持” 評級。貝倫貝格銀行（Berenberg Bank）在 9 月 17 日的研究報告中將艾伯維的評級從 “持有” 上調至 “買入”，並將其目標股價從 170.00 美元上調至 270.00 美元。Cantor Fitzgerald 在 9 月 15 日的研究報告中將艾伯維的目標股價從 215.00 美元上調至 245.00 美元，並給予該公司 “增持” 評級。Evercore ISI 在 9 月 22 日的報告中將艾伯維的目標股價從 207.00 美元上調至 222.00 美元，並給予該公司 “跑贏大盤” 評級。最後，派珀·桑德勒（Piper Sandler）在 8 月 12 日的報告中開始覆蓋艾伯維的股票。他們給予 “增持” 評級，並設定 231.00 美元的目標股價。四位股票研究分析師對該股票給予強烈買入評級，十七位給予買入評級，八位給予持有評級。根據 MarketBeat 的數據，艾伯維的共識評級為 “適度買入”，共識目標價為 223.52 美元。</p>
</div><ul>
<li>AbbVie Stock Eyes Breakout as Pipeline and Profits Grow</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯維股票關注突破，管道與利潤增長</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on ABBV</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 ABBV 的最新股票分析</strong></p>
</div><h2>AbbVie Stock Down 3.0%</h2>
<div class="lb-trans"><h2>艾伯維股票下跌 3.0%</h2>
</div><p>Shares of ABBV opened at $236.98 on Friday. AbbVie Inc. has a 12 month low of $163.81 and a 12 month high of $244.81. The firm's 50 day moving average is $209.90 and its 200-day moving average is $195.87. The stock has a market capitalization of $418.63 billion, a PE ratio of 112.85, a P/E/G ratio of 1.43 and a beta of 0.51. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14.</p>
<div class="lb-trans"><p>艾伯維（ABBV）股票在週五開盤價為 236.98 美元。艾伯維公司 12 個月低點為 163.81 美元，12 個月高點為 244.81 美元。該公司的 50 日移動平均線為 209.90 美元，200 日移動平均線為 195.87 美元。該股票的市值為 4186.3 億美元，市盈率為 112.85，市盈增長比率為 1.43，貝塔值為 0.51。該公司的流動比率為 0.74，速動比率為 0.61，債務與股本比率為 44.14。</p>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物科技巨頭受益於美國銷售和政策變化</li>
</ul>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing the consensus estimate of $3.24 by ($0.27). AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. During the same period in the prior year, the business posted $2.65 earnings per share. The firm's revenue for the quarter was up 6.6% compared to the same quarter last year. Equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.</p>
<div class="lb-trans"><p>艾伯維（NYSE:ABBV - 獲取免費報告）最近在 7 月 31 日宣佈了其財報。該公司報告本季度每股收益為 2.97 美元，低於共識預期的 3.24 美元，差額為 0.27 美元。艾伯維的股本回報率為 699.66%，淨利潤率為 6.45%。該公司本季度的收入為 154.2 億美元，而共識預期為 149.3 億美元。去年同期，該公司的每股收益為 2.65 美元。與去年同期相比，該公司的季度收入增長了 6.6%。股票研究分析師預測，艾伯維公司今年將發佈 12.31 美元的每股收益。</p>
</div><h2>AbbVie Announces Dividend</h2>
<div class="lb-trans"><h2>艾伯維宣佈分紅</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Friday, November 14th. Investors of record on Wednesday, October 15th will be given a $1.64 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie's dividend payout ratio (DPR) is presently 312.38%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了季度分紅，將於 11 月 14 日（星期五）支付。10 月 15 日（星期三）的登記投資者將獲得 1.64 美元的分紅。除息日為 10 月 15 日（星期三）。這代表着年化分紅為 6.56 美元，分紅收益率為 2.8%。艾伯維的分紅支付比率（DPR）目前為 312.38%。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares of the company's stock, valued at $35,178,278.64. This trade represents a 19.29% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, EVP Nicholas Donoghoe sold 13,295 shares of the firm's stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the completion of the transaction, the executive vice president directly owned 58,247 shares in the company, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他艾伯維新聞中，執行副總裁 Azita Saleki-Gerhardt 於 8 月 12 日出售了 42,370 股該公司的股票。該股票以平均價格 198.42 美元出售，總價值為 8,407,055.40 美元。交易完成後，該執行副總裁直接持有 177,292 股該公司的股票，價值 35,178,278.64 美元。此交易代表其持股減少了 19.29%。該交易已在向證券交易委員會的備案中披露，相關信息可通過 SEC 網站訪問。此外，執行副總裁 Nicholas Donoghoe 於 8 月 5 日出售了 13,295 股該公司的股票。該股票以平均價格 198.51 美元出售，總交易額為 2,639,190.45 美元。交易完成後，該執行副總裁直接持有 58,247 股該公司的股票，價值約 11,562,611.97 美元。這代表其持股減少了 18.58%。該銷售的披露信息可在此處找到。公司內部人士目前持有 0.25% 的股票。</p>
</div><h2>AbbVie Company Profile</h2>
<div class="lb-trans"><h2>艾伯維公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯維公司在全球範圍內發現、開發、生產和銷售藥品。該公司提供的藥物包括：Humira，一種用於自身免疫性疾病和腸道貝赫切特病及膿皰性壞死性皮膚病的注射劑；Skyrizi，用於治療中度至重度斑塊型銀屑病、銀屑病性疾病和克羅恩病；Rinvoq，用於治療類風濕性關節炎、銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸性脊柱關節炎、潰瘍性結腸炎和克羅恩病；Imbruvica，用於治療成人血癌患者；Epkinly，用於治療淋巴瘤；Elahere，用於治療癌症；以及 Venclexta/Venclyxto，用於治療血癌。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>General Dynamics Hits New Highs: Why It Might Keep Climbing</li>
<li>How to Calculate Stock Profit</li>
<li>Nike’s Turnaround: If the Shoe Fits, Buy It!</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>NVIDIA Breaks Out to New Highs: What Comes Next?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比艾伯維更好的股票</li>
<li>投資者如何識別併成功交易下跌缺口股票</li>
<li>通用動力創下新高：為什麼它可能會繼續上漲</li>
<li>如何計算股票利潤</li>
<li>耐克的逆轉：如果鞋子合適，就買下它！</li>
<li>如何有效使用 MarketBeat 評級篩選器</li>
<li>英偉達突破新高：接下來會發生什麼？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在艾伯維嗎？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮艾伯維之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而艾伯維並不在名單上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然艾伯維目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Capital & Planning LLC 出售了 5,000 股艾伯維公司（AbbVie Inc.）的股票，代碼為$ABBV